Online inquiry

IVTScrip™ mRNA-Human ADGRE3, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WK10738MR)

This product GTTS-WK10738MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the ADGRE3 protein. This product can be used in Monocyte-related researches.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Human
RefSeq NM_001289158.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 84658
UniProt ID Q9BY15
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human ADGRE3, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WK10738MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WK28733MR IVTScrip™ mRNA-Human ASXL3, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ASXL3
GTTS-WK22617MR IVTScrip™ mRNA-Human ARHGEF33, (Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ARHGEF33
GTTS-WK11378MR IVTScrip™ mRNA-Human AFAP1, (Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AFAP1
GTTS-WK16744MR IVTScrip™ mRNA-Human Annexin V, (Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Annexin V
GTTS-WK19724MR IVTScrip™ mRNA-Human ANKRD39, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ANKRD39
GTTS-WK26866MR IVTScrip™ mRNA-Human ARPC1B, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ARPC1B
GTTS-WK24445MR IVTScrip™ mRNA-Human ARL5B, (Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ARL5B
GTTS-WK19160MR IVTScrip™ mRNA-Human ANXA2R, (Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ANXA2R
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW